

## **Notice Regarding Adjustment of 340B Prices for Select Products of Novo Nordisk Inc.**

Novo Nordisk Inc. has recalculated its 340B ceiling prices for the period Q1-Q2 2020 for the products listed below due to revisions made to their Medicaid pricing data. Novo Nordisk Inc. has asked the Office of Pharmacy Affairs (OPA) within HRSA to post this Notice on the public website to ensure transparency by providing access to information about Novo Nordisk Inc.'s recalculation affecting certain 340B Covered Entities for the impacted product(s).

Novo Nordisk Inc. has determined the credit amount owed to each affected covered entity. Novo Nordisk Inc. will be working through Apexus, the HRSA 340B Prime Vendor, to issue refunds for each affected Covered Entity. Refunds will be issued either to a Covered Entity's validated wholesaler pharmacy account when one can be identified, or a check will be issued to Covered Entities whose wholesaler account cannot be identified.

<b><u>NDC</u></b>	<b><u>Product Description</u></b>
00169-7810-01	NOVOEIGHT® 1000 IU
00169-7815-01	NOVOEIGHT® 1500 IU
00169-7820-01	NOVOEIGHT® 2000 IU
00169-7825-01	NOVOEIGHT® 250 IU
00169-7830-01	NOVOEIGHT® 3000 IU
00169-7850-01	NOVOEIGHT® 500 IU

If a Covered Entity believes they are due a refund and are not contacted by Apexus by January 30, 2023, you may contact Novo Nordisk Inc., at [NNIBIDNOTIFICATION@novonordisk.com](mailto:NNIBIDNOTIFICATION@novonordisk.com).